RougeTx Launches with $58M to Tackle Rare Bleeding Disorder - European Biotechnology Magazine

RougeTx Raises $58 Million to Advance Oral Treatment for Hereditary Hemorrhagic Telangiectasia

RougeTx, a spinout from Leiden University Medical Center, has secured $58 million in Series A funding to advance an oral small molecule treatment for hereditary hemorrhagic telangiectasia (HHT) into clinical trials. The company aims to address the underlying pathology of the condition by reattaching pericytes to blood vessel walls, a process intended to stabilize vessels

RougeTx launches with $58M to tackle rare bleeding disorder - European Biotechnology Magazine

Dutch biotech RougeTx has launched with a $58 million (€52 million) series A to take its lead drug RTX-001 toward first-in-human testing in hereditary hemorrhagic telangiectasia (HHT). The round was co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners, with the European Investment Bank (EIB) participating through Angelini's Aurea co-investment vehicle.

RougeTx Launches with $58 Million Series A Financing to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia

Series A co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners, with participation from Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest and Kerna Ventures. Financing will advance a potential once-daily oral treatment designed to restore blood vessel stability in HHT, a serious inherited bleeding disorder with no approved therapies. periSCOPE platform […] The post RougeTx Launches with $58 Million S…